Demo Mode
EBITDA Impact
Dashboards show numbers. Kincaid IQ shows receipts.
Demo dataset (illustrative). No client data.
Step 1 of 2
Signals that hit EBITDA first
A small set of drivers explains most of the PMPM trend and renewal pressure.
NET_COST_PMPM
Net Cost PMPM
612.40USD
Confidence:88%
TREND_YOY
Trend YoY
0.11%
Confidence:84%
PHARMACY_SHARE
Pharmacy Share of Total
0.30%
Confidence:80%
STOPLOSS_VOLATILITY
Stop-Loss Volatility Index
0.67
Confidence:78%
Decision Levers
These are the moves a CFO can defend with evidence.
Specialty site-of-care optimization
medExpected impact:-2.1 PMPM
Timeframe:60-120 days
Impact range:
-1.2 to -3.4 PMPM
GLP-1 guardrails (clinical + financial)
medExpected impact:-1.4 PMPM
Timeframe:30-60 days
Impact range:
-0.8 to -2.2 PMPM
Stop-loss strategy reset (runway + lasers)
highExpected impact:-0.9 PMPM
Timeframe:Next renewal
Impact range:
-0.4 to -1.6 PMPM
Want this on your data?
We can run a renewal-grade readout using your claims + contracts and produce board-ready receipts.
